Editorial Notes
Amendments

2024—Par. (15). Pub. L. 118–186 added par. (15).

2018—Par. (2). Pub. L. 115–278, § 2(g)(3)(A)(i), substituted “biological,” for “biological,,”.

Par. (3). Pub. L. 115–278, § 2(g)(3)(A)(ii), substituted “Director of the Cybersecurity and Infrastructure Security Agency” for “Assistant Secretary for Infrastructure Protection”.

Par. (5)(A). Pub. L. 115–278, § 2(g)(3)(A)(i), substituted “biological,” for “biological,,”.

2007—Par. (3). Pub. L. 110–53 substituted “Under Secretary for Intelligence and Analysis and the Assistant Secretary for Infrastructure Protection” for “Under Secretary for Information Analysis and Infrastructure Protection”.

2006—Pars. (2), (5)(A). Pub. L. 109–347 struck out “radiological, nuclear” after “biological,”.

Statutory Notes and Related Subsidiaries
Rule of Construction

Pub. L. 118–186, § 4, Dec. 23, 2024, 138 Stat. 2637, provided that: “Nothing in this Act [amending this section and enacting provisions set out as a note below] may be construed to limit the authority of agencies currently managing, overseeing, or otherwise involved in drug equipment and reference libraries.”

Requirements

Pub. L. 118–186, § 3, Dec. 23, 2024, 138 Stat. 2637, provided that: “In carrying out section 302(15) of the Homeland Security Act of 2002 [6 U.S.C. 182(15)], as added by section 2, the Under Secretary for Science and Technology shall—

“(1)
follow the recommendations, guidelines, and best practices described in the Artificial Intelligence Risk Management Framework (NIST AI 100–1) or any successor document published by the National Institute of Standards and Technology; and
“(2)
establish the Directorate of Science and Technology’s research, development, testing, evaluation, and cost-benefit analysis priorities under such section 302(15) based on the latest available information, including specific drugs identified as threats in—
“(A)
the latest Homeland Threat Assessment published by the Department of Homeland Security;
“(B)
the latest State and Territory Report on Enduring and Emerging Threats published by the Drug Enforcement Administration; or
“(C)
any successor documents.”